Hints and tips:
...Gilead’s $88-a-share cash offer represents a 108 per cent premium to Immunomedics’ closing price on Friday....
...Shares in Immunomedics are up almost 100 per cent year to date. Gilead and Immunomedics did not immediately respond to a request for comment....
...million (WSJ) Ron Perelman sells stake in Scientific Games to Australia’s Caledonia (FT) Gojek and Grab renew tie-up talks as SoftBank’s Son backs deal (FT) Gilead ramps up Cancer focus with $21 billion immunomedics...
...Investors are watching for data from a trial of a drug made by Immunomedics, a New Jersey-based biotech....
...Drug stocks were led higher by Belgium’s UCB , which climbed 1.6 per cent to €32.28 after a licence agreement with Immunomedics of the US for its lupus drug....
International Edition